Ray brings the experience, knowledge and personal network from more than 20 highly productive years in regional and global leadership positions spanning the complete value chain in the Pharmaceutical and Biotechnology industries. Having completed his PhD at University of Manchester, UK in 1994 and a post-doctoral fellowship at McGill University in Canada, Ray joined the Technology Access and Strategic Alliances Team at Zeneca in 1995, becoming the Team Leader only a few years later. After the merger with Astra, Ray took a global management role, in-licensing new technologies and developing molecules in oncology, cardiovascular, respiratory and inflammatory disease areas, while concurrently obtaining an MBA (with distinction) at the Manchester Business School. He then moved into Business Development as a Senior Analyst and then Director of Corporate Development, where he spearheaded a number of transactions and contributed to shaping AstraZeneca’s strategic roadmap, including its entry into biologics. Following a period leading regional commercial operations for AstraZeneca in 14 European countries and Russia, Ray moved to senior business development roles in the biotech sector, where he out-licensed a portfolio of Meningitis B assets to Sanofi, and was involved in successfully listing Emergent Solutions, Inc. (EBS) on NASDAQ. Ray also ran his own business (BD Solutions Limited) for five years, advising clients on corporate development and commercialisation, including as CEO of Asterion Limited, where he successfully closed deals with Genzyme Inc. and Ipsen. Ray joined Crucell NV in 2010 and was part of the team instrumental in its sale to Johnson & Johnson, for whom he orchestrated deals in infectious diseases and vaccines before becoming Executive Director of Corporate Development at Amgen in 2012. In this role, Ray closed immuno-oncology deals with Boehringer Ingelheim, negotiated international commercial deals with GSK, Mitsubishi Tanabe and Novartis, and played a key part in the acquisition of Onyx Pharmaceuticals Inc. and Dezima Pharma BV. Ray took up the role of Chief Executive Officer at e-therapeutics on 6 April 2017.
After qualifying as a Chartered Accountant Steve spent the following 20 years working in the City of London in investment banking. During this time he was involved in numerous fund raises and corporate transactions and has significant experience talking to professional investors and advising companies. He advised the Company on the £40m fund raise in 2013 and joined as CFO the following year.
Iain Ross has over 40 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions, and >25 years in cross-border management as a Chairman and CEO. He has led and participated in 5 Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim. Currently he is Non-Executive Chairman of Redx Pharma plc (LSE) and Kazia Therapeutics Limited (ASX & NASDAQ) and a Non-Executive Director of Biomer Technology Limited. He is a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University. Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc where as Chief Executive Officer of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit before the sale to Lonza. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. Iain was appointed to the Board of e-Therapeutics in January 2016. He continues to consult for private equity groups on biotech & technology company turnarounds.
Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotech industry as well as in academia. He is currently a Non-Executive Director of the life sciences investment company Arix Bioscience plc. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities. Previously, Trevor held significant roles in industry including Director of Allergan Inc from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987-1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry (ABPI), board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research. He joined the e-Therapeutics board in October 2015.
Christine, a chartered accountant, has some 30 years' experience in the life sciences sector, spanning a broad range of technologies and products from genetic discovery through drug development, branded pharmaceuticals and generics and medical devices. She has served as Chief Financial Officer and Chief Operating Officer and as non-executive director in a range of public and private companies and completed several public and private financing transactions and been instrumental in completing numerous M&A and licensing transactions and business restructurings, both in the UK and internationally. Christine is currently Chief Financial Officer of Acacia Pharma Group plc and a non-executive director of Fertility Focus Limited and Futurenova Limited. Previously, Christine served as Chief Financial Officer and then non-executive director of AIM-listed Electrical Geodesics, Inc. which was recently acquired by Philips NV, following roles as CFO of Optos plc, BTG plc, Oxagen Limited and Celltech-Chiroscience Group plc having started her life-sciences career as Financial Controller of Medeva plc. She joined the board of e-Therapeutics on 1 November 2017.